Enzo Biochem Inc (NYSE:ENZ)
| 2.28 Data as of May 17 |  +0.03 / +1.33%Today’s Change | 1.33 Today|||52-Week Range 3.16 | -15.56% Year-to-Date |
Latest ENZ News | Press Releases
No recent news for Enzo Biochem Inc.
Today’s Trading
| Previous close | 2.25 |
| Today’s open | 2.25 |
| Day’s range | 2.25 - 2.28 |
| Volume | 67,864 |
| Average volume (3 months) | 102,803 |
| Market cap | $108.0M |
| Dividend yield | -- |
Data as of 4:03pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -197.06% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +1.03% |
| P/E ratio | NM |
| Price/Sales | 0.56 |
| Price/Book | 1.82 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ONTYOncothyreon Inc | +0.02 | +1.02% |
| BSTCBiospecifics Technol... | +0.17 | +1.08% |
| CDXSCodexis Inc | +0.03 | +1.26% |
| PBMDPrima BioMed Ltd | -0.43 | -15.47% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Last reporting date | June 12, 2012 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $103.1M |
| Annual profit (last year) | -$39.3M |
| Net profit margin | -38.09% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman, Chief Executive Officer & Secretary Elazar Rabbani, PhD |
President, CFO, Treasurer, Director & CAO Barry W. Weiner, MBA |
Corporate headquarters New York, New York |
Forecasts
